Premium
[IC‐P‐125]: WHITE MATTER LESIONS’ EFFECTS ON CEREBRAL BLOOD FLOW IN MULTIPLE CORTICAL REGIONS ARE INDEPENDENT OF AMYLOID DEPOSITION IN COGNITIVELY NORMAL ELDERLY
Author(s) -
Song Zhuang,
Lu Hanzhang,
Liu Peiying,
Park Denise C.
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.2399
Subject(s) - cerebral blood flow , hyperintensity , atrophy , white matter , temporal lobe , cardiology , pittsburgh compound b , psychology , neuroscience , alzheimer's disease , medicine , pathology , magnetic resonance imaging , disease , radiology , epilepsy
evaluated. This results in major data loss as 70-80% of all data is discarded due to identification failure when running endogenous peptides. We propose a new quantificationdriven approach using a clustering algorithm to mathematically search for similar spectra across samples and compare their abundances across patient groups. We prove this concept by employing the approach on a patient cohort consisting of 40 AD patients, 40 healthy controls (HC) and 40 mild cognitive impairment (MCI) patients. Results: Using our novel approach a new potential biomarker of AD, a peptide from the protein pleiotrophin, was identified. The AD group had significantly (p < .05) higher concentrations (222% increase) of this peptide as compared to the HC group. The MCI patients had intermediate levels. We also validated this finding and found a similar pattern of increased concentrations of the pleiotrophin peptide in AD in an independent patient material consisting of 15 AD, 15 Parkinson disease (PD), 15 progressive supranuclear palsy (PSP) and 15 HC subjects. The increased concentrations in AD vs HC were significant (p < .05) but less prominent here (38%). There were also significantly increased concentrations in AD vs PD (37%, p < .05) and AD vs PSP (20%, p < .05). Conclusions:Pleiotrophin is a potential new biomarker for AD, and the results of this study indicate that it might be an early and specific biomarker of AD pathology. The results of this study are proof-of-concept for our proposed new strategy of quantification-driven clinical mass spectrometry data analysis.